Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

Zarębska-Michaluk, Dorota; Piekarska, Anna; Jaroszewicz, Jerzy; Klapaczyński, Jakub; Mazur, Włodzimierz; Krygier, Rafał; Belica-Wdowik, Teresa; Baka-Ćwierz, Barbara; Janczewska, Ewa; Pabjan, Paweł; Dobracka, Beata; Lorenc, Beata; Tudrujek-Zdunek, Magdalena; Tomasiewicz, Krzysztof; Sitko, Marek; Garlicki, Aleksander; Czauż-Andrzejuk, Agnieszka; Citko, Jolanta; Dybowska, Dorota; Halota, Waldemar; Pawłowska, Małgorzata; Laurans, Łukasz; Deroń, Zbigniew; Buczyńska, Iwona; Simon, Krzysztof; Białkowska, Jolanta; Tronina, Olga; Flisiak, Robert

doi:10.1016/j.advms.2019.09.002

Cited by 6 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher efficacy for a 12-week regimen as compared to an 8-week option in GT1b infected patients with non-advanced liver fibrosis was also observed in 771 patients from the RWE EpiTer-2 study [17]. In contrast, Manuc et al [18] documented the same response rate of 96% for 8-and 12-week regimens in the RWE cohort of 1436 GT1b infected patients, and the only predictive factor for non-response was male sex, which supported our findings.…”

Section: Discussionmentioning

confidence: 81%

Genotype-specific versus pangenotypic regimens in patients infected with HCV genotype 1b in real-world settings

Pabjan¹,

Brzdęk²,

Chrapek³

et al. 2021

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

The introduction of direct-acting antivirals (DAA) has provided us with hope to eliminate the hepatitis C virus (HCV) infection as a significant public problem in upcoming years. This study compares genotype-specific and pangenotypic regimens in patients with genotype (GT) 1b infection, being the most common GT in Poland. We have confirmed the very high effectiveness and a good safety profile with no significant differences between these two generations of the drug. Male sex and previous treatment with DAA were identified as negative predictors of therapy efficacy. To the best of our knowledge, the presented results of our research have been so far the only study of this type comparing the effectiveness and safety of both generations of drugs within one protocol carried out by the same researchers.

show abstract

Section: Discussionmentioning

confidence: 81%

Genotype-specific versus pangenotypic regimens in patients infected with HCV genotype 1b in real-world settings

Pabjan¹,

Brzdęk²,

Chrapek³

et al. 2021

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chronic HBV viral hepatitis is usually accompanied by liver fibrosis of varying degrees. Because of the persistent presence of the virus, repeated or continuous inflammatory infiltration can lead to pathological changes such as inflammation and necrosis in liver parenchyma, resulting in continuous fibrous hyperplasia of the liver and the formation of hepatic fibrosis [13]. Studies have shown that the level of CIV increased significantly in the serum of patients with chronic active hepatitis, cirrhosis, and hepatocellular carcinoma [14].…”

Section: Discussionmentioning

confidence: 99%

Receiver Operator Characteristics (ROC) Analysis of Real-Time Shear Wave Elastography Information Health Monitoring in Liver Fibrosis with Chronic Hepatitis B Virus Infection

Zhao

Chen

Zhang

et al. 2021

Scientific Programming

View full text Add to dashboard Cite

To investigate the effectiveness of shear-wave elastography (SWE) based on e-health in diagnosing liver fibrosis in patients infected with hepatitis B virus (HBV) and provide theoretical basis for early diagnosis and treatment of patients with chronic HBV infection, in this study, 73 patients with chronic HBV infection who underwent e-health SWE examination were divided into chronic hepatitis B group (51 cases) and hepatitis B cirrhosis group (22 cases), and another 20 healthy volunteers were introduced as control. The contents of second liver two half-and-half, hyaluronic acid (HA) of liver fibrosis, laminin (LN), pAUVollagen III N terminal peptide (PIII NP), collage type IV (CIV), and HBV-DNA were detected. SWE was used to measure the elastic modulus in the S2 and S3 segments of the left outer lobe of the liver, S4 segment of the left inner lobe of the liver, S5 and S8 segments of the right anterior lobe of the liver, and S6 and S7 segments of the right posterior lobe of the liver. Finally, the correlations between the four examination results of liver fibrosis and the elastic modulus values were compared, and the receiver operator characteristic curve (ROC) for SWE technical diagnosis was drawn. The results showed that there was no significant difference in HBV-DNA content between the two groups ( P > 0.05 ); the contents of alanine transaminase (ALT) and aspartate aminotransferase (AST) in the blood of chronic hepatitis B group were significantly higher than those in the liver cirrhosis group ( P < 0.05 ); HA, PIII NP, and CIV contents were significantly lower than the liver cirrhosis group ( P < 0.05 ); the success rates of SWE detection in S5 and S6 segments of the two groups were 100.00%, and the elastic modulus of the hepatitis B cirrhosis group was significantly higher than that of the chronic hepatitis B group ( P < 0.05 ); correlation results showed HA, PIII NP, and CIV of two groups of patients and elastic modulus value in S5 and S6 segments showed positive correlation ( P < 0.05 ); ROC curve analysis showed that AUC (area under the curve) was 0.866, the sensitivity was 89.59%, and the specificity was 76.49%, which indicated that the liver elastic modulus value measured by e-health SWE technology can quantitatively show liver fibrosis in patients with chronic HBV infection, and its application in the diagnosis of clinical liver fibrosis was real and feasible.

show abstract

“…Finally, after the Garnet study treatment-naïve patients with minimal to moderate fibrosis, infected with GT1b, became eligible to receive the OBV/PTV/r + DSV regimen for 8 weeks only. The high efficacy of the shortened treatment course in this subpopulation was confirmed by real-world studies, but according to the EpiTer-2 decision on shortening one should be careful in males because of the SVR reduction risk [32-34].…”

Section: Genotype Specific Direct Acting Antiviralsmentioning

confidence: 98%

Viral hepatitis C treatment shortening – what is the limit?

Zarębska-Michaluk

2019

ceh

Self Cite

View full text Add to dashboard Cite

Successful antiviral treatment for hepatitis C virus (HCV) infection is crucial to prevent progression of the disease and its most serious complications. Therapy options have changed over the years with improvement of treatment efficacy, safety and simplification. They evolved from interferon and ribavirin combination administered for 24-72 weeks through interferon (IFN)-based triple therapies with 24-48 weeks duration to the all-oral, well-tolerated direct-acting antiviral regimens lasting for 8-16 weeks and with almost 100% cure rates. The benefits of shorter treatment duration are cost reduction, access to therapy for more patients, and lower risk of adverse events and nonadherence. This review summarizes data on treatment options, focusing on the recommended durations of different regimens depending on HCV genotype, severity of liver disease and history of previous therapy. According to currently available data, shortening treatment below 8 weeks does not provide additional benefits, although the further simplification of therapy is still a subject of study.

show abstract

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

Cited by 6 publications

References 21 publications

Genotype-specific versus pangenotypic regimens in patients infected with HCV genotype 1b in real-world settings

Genotype-specific versus pangenotypic regimens in patients infected with HCV genotype 1b in real-world settings

Receiver Operator Characteristics (ROC) Analysis of Real-Time Shear Wave Elastography Information Health Monitoring in Liver Fibrosis with Chronic Hepatitis B Virus Infection

Viral hepatitis C treatment shortening – what is the limit?

Contact Info

Product

Resources

About